Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Rituximab can cause skin issues, but baricitinib may help improve them.

Baricitinib helps regrow hair in teens with severe alopecia areata.

The combination of encorafenib and binimetinib caused few skin issues.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Upadacitinib improved multiple immune-related conditions in one patient.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Ruxolitinib cream may help treat severe hair loss in children.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Afatinib often causes skin problems that need proactive management.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.